CMPX · NASDAQ
Compass Therapeutics, Inc.
$0.76 -0.04 (-5.18%)
Company overview
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $137M
- Employees
- 35
- Headquarters
- Boston, MA
- Website
- compasstherapeutics.com
- CEO
- Thomas J. Schuetz
- Listed
- April 5, 2021
- P/E
- -1.79
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- -$738,000
- Operating income
- -$75.2M
- EBITDA
- -$72.5M
- Net income
- -$68.2M
- EPS
- -$0.43
- Total assets
- $205M
- Total debt
- $9.8M
- Earnings yield
- -55.92%
CMPX
1D
NASDAQ
O0.78H0.81L0.75C0.76-0.04 (-5.18%)Vol643.08K